根据最新提交给美国证券交易委员会（SEC）的文件显示，Reviva Pharmaceuticals Holdings, Inc. 正计划将其核心药物Brilaroxazine的专利寿命和市场独占期进行延长。
这一战略举措若获批准，有望将该药物的专利保护期限延续至2046年，从而为公司提供更长的独家销售窗口，巩固其在相关治疗领域的市场地位。
根据最新提交给美国证券交易委员会（SEC）的文件显示，Reviva Pharmaceuticals Holdings, Inc. 正计划将其核心药物Brilaroxazine的专利寿命和市场独占期进行延长。
这一战略举措若获批准，有望将该药物的专利保护期限延续至2046年，从而为公司提供更长的独家销售窗口，巩固其在相关治疗领域的市场地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.